GGCT participates in the malignant process of hepatocellular cancer cells by regulating the PTEN/PI3K/AKT pathway through binding to EZH2

• Published in: Discover. Oncology Vol. 16; no. 1; pp. 129 - 12
• Main Authors: He, Junbo, Wang, Liangzhi, Lv, Mengjia, Yuan, Yiming
• Format: Journal Article
• Language: English
• Published: New York Springer US 07.02.2025; Springer Nature B.V; Springer
• Subjects: Antibodies; Apoptosis; Cancer Research; Cancer therapies; Cell growth; Enhancer of zeste homolog 2; Flow cytometry; Glycolysis; Hepatocellular carcinoma; Internal Medicine; Liver cancer; Medical prognosis; Medicine; Medicine & Public Health; Molecular Medicine; Oncology; Proteins; PTEN/PI3K/AKT; Radiotherapy; Surgical Oncology; Tumors; γ-Glutamylcyclotransferase; United States > US; China; Shanghai China; Glycolysis; γ-Glutamylcyclotransferase; Hepatocellular carcinoma; PTEN/PI3K/AKT; Enhancer of zeste homolog 2

Background γ-Glutamylcyclotransferase (GGCT) is implicated in multiple types of cancer diseases. Nevertheless, the roles and relevant mechanisms of GGCT in hepatocellular carcinoma (HCC) remain vague. Methods GGCT expression in HCC and its effect on patient survival curve in HCC were evaluated utili...